AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Jordi Bertran-Alamillo, Valérie Cattan, Marie Schoumacher and 15 more
Nature Communications · 2019
doi:10.1038/s41467-019-09734-5 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Non-small cell lung cancer with EGFR mutations are known to develop resistance to EGFR tyrosine kinase inhibitors. Here, the authors show AURKB activation to be associated with resistance in EGFR mutant lung cancer cells, and that AURKB is a therapeutic target in resistant tumours that lack the p.T790M or other acquired mutations.
Abstract licence: CC BY-NC-ND
Cited by papers we hold1
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.